---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-337964"
form_type: "8-K"
ticker: "EVMN"
cik: "0002044725"
company_name: "Evommune, Inc."
filed_at: "2026-08-06T20:06:15+00:00"
generated_at: "2026-08-06T20:08:44.405219+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Evommune Q2 net loss $32.2M; EVO756 AD Phase 2b data due Sept 2026

## Summary
- Net loss of $32.2M for Q2 2026 vs $13.6M in Q2 2025; cash $288M as of June 30, 2026.
- EVO756 Phase 2b top-line data in moderate-to-severe atopic dermatitis expected September 2026.
- EVO756 migraine prophylaxis Phase 2b trial initiated; top-line data anticipated in 2027.
- Discontinued EVO756 development in chronic spontaneous urticaria after Phase 2b missed primary endpoint.
- EVO301 Phase 2a full positive data set in AD to be presented at upcoming medical conference; Phase 2b to start mid-2027.

## SEC filing metadata
- accession: 0001193125-26-337964
- form_type: 8-K
- ticker: EVMN
- cik: 0002044725
- company_name: Evommune, Inc.
- filed_at: 2026-08-06T20:06:15+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2044725/000119312526337964/0001193125-26-337964-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2044725/000119312526337964/evmn-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-337964
- JSON: https://secwatch.observer/filing/0001193125-26-337964.json
- Plain text: https://secwatch.observer/filing/0001193125-26-337964.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.